close
close

Artificial Intelligence and Antitrust Considerations in US Healthcare

*/ .cpi-spinner-loader { width: 60px; aspect ratio: 2; –_g: radial gradient without repeats (nearest page circle, #000 90%, #0000); background: var(–_g) 0% 50%, var(–_g) 50% 50%, var(–_g) 100% 50%; backgroundsize: calc(100%/3) 50%; animation: l3 1s infinite linear; } @keyframes l3 { 20%{background position:0% 0%, 50% 50%,100% 50%} 40%{background position:0% 100%, 50% 0%,100% 50%} 60% {background position:0% 50%, 50% 100%,100% 0%} 80%{background position:0% 50%, 50% 50%,100% 100%} }

Artificial intelligence – the “new thing” in antitrust law – continues to permeate the healthcare industry in the United States. Competition law requires both an awareness of the risks of anticompetitive behavior resulting from a company’s reliance on AI and an awareness that federal and state antitrust enforcement authorities, including the Department of Justice’s Antitrust Division and the Federal Trade Commission, are watching how companies use AI in their business practices. Thi

THIS ITEM IS NOT AVAILABLE FOR IP ADDRESS 159.203.166.91

Please verify your email address or join us to access premium content!